Group 1 - The latest shareholder equity disclosures for four companies were made on December 2, 2025, including Stone Four Pharmaceutical Group, Yongtai Properties, Global New Materials International, and Huatai Textile [1] Group 2 - Stone Four Pharmaceutical Group (02005) saw a slight increase in holdings by China Pharmaceutical Company Limited from 889 million shares to 890 million shares, representing a holding percentage change from 30.13% to 30.17% [2] - The same company, Stone Four Pharmaceutical Group, also had an increase in holdings by Qu Jiguang from 1.227 billion shares to 1.228 billion shares, with a holding percentage change from 41.56% to 41.60% [2] - Yongtai Properties (00369) reported no holdings from Wu Dewei, with a change from 0 shares to 0%, down from 0.12% previously [2] - Global New Materials International (06616) experienced a decrease in holdings by Hu Yongxiang from 19.1592 million shares to 19.0152 million shares, with a holding percentage change from 1.54% to 1.53% [2] - Huatai Textile (01382) saw an increase in holdings by Shi Guorong from 650,000 shares to 1.38 million shares, with a holding percentage change from 0.05% to 0.10% [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 石四藥集團有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02005 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.02 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.02 | HKD | | 200,000,000 | 本月底法定 ...

Group 1 - The latest shareholder equity disclosures for FAST RETAIL-DRS, 石四药集团, and LFG Investment Holdings were made on December 1, 2025 [1] Group 2 - For FAST RETAIL, Yanai Tadashi reduced his holdings from 76.3054 million shares to 74.7154 million shares, representing a holding percentage of 23.47% [2] - 石四药集团's 曲继广 increased his holdings slightly from 1.226 billion shares to 1.227 billion shares, with a holding percentage of 41.56% [2] - LFG Investment Holdings' 黄浩麒 decreased his holdings from 200,000 shares to 100,000 shares, resulting in a holding percentage of 0.02% [2] - China Pharmaceutical Company Limited maintained its holdings in 石四药集团 at 889 million shares, with a holding percentage of 30.13% [2]

Major Events - Excellence Risen (02687) plans to offer 6.6667 million H-shares globally from November 28 to December 3 [1] - Naxin Micro (02676) plans to offer 19.0684 million shares globally from November 28 to December 3 [1] - Stone Four Pharmaceutical Group (02005) received production registration approval for the sustained-release capsule of Tofacitinib (4mg) [1] - Innovent Biologics (01801) received approval from the National Medical Products Administration for its drug, Xinmeiyue® (Pikankizumab injection), for treating moderate to severe plaque psoriasis [1] - Jiangxi Copper (00358) intends to acquire shares of the overseas-listed company SolGold Plc [1] - ZTO Express-W (02057) plans to acquire 100% equity of Zhejiang Xinglian for 178 million yuan to enhance end-to-end domestic and international air logistics capabilities [1] - China Shenhua (01088) completed 168 hours of trial operation for the Beihai Phase II Unit 3 and transferred it to commercial operation [1] - Zhidatech (02650) signed a major contract worth over 100 million yuan for electric vehicle charging stations with Saudi Controls Ltd, expanding into the Middle East market [1] - Hendry (03389) received a voluntary cash offer from Junya at a 12% premium and will resume trading on December 1 [1] - Zijin Mining (02899) donated 20 million HKD to support post-fire reconstruction in Hong Kong's Tai Po District [1] - Guoquan (02517) donated 10 million HKD for fire rescue efforts in Hong Kong's Tai Po [1] - InnoCare Pharma (02577) donated 2 million HKD to assist in fire rescue efforts in Hong Kong's Tai Po [1] Operating Performance - Meituan-W (03690) reported Q3 revenue of approximately 95.5 billion HKD, a year-on-year increase of about 2%, with highlights in flash purchase and global expansion [1] - China Gas (00384) reported a mid-term profit attributable to shareholders of 1.334 billion HKD, with an interim dividend of 0.15 HKD per share [1] - Zhixing Group Holdings (01539) reported a mid-term profit attributable to shareholders of 27.533 million HKD, a year-on-year increase of 35.68%, with gross margin rising to approximately 67.3% [1] - Guofu Quantum (00290) reported mid-term revenue of 1.027 billion HKD, a year-on-year increase of 4564.52% [1] - Yuhua Education (06169) reported an annual adjusted profit attributable to shareholders of 914 million HKD, a year-on-year increase of 95.6% [1] - China Water Affairs (00855) achieved mid-term revenue of approximately 5.183 billion HKD, with a dividend of 0.13 HKD per share [1] - Zhonghui Group (00382) reported annual revenue of approximately 2.489 billion HKD, a year-on-year increase of 7.7% [1]

Core Viewpoint - The company, Stone Four Pharmaceutical Group, has received production registration approval from the National Medical Products Administration of China for its sustained-release capsules of Trospium Chloride (4mg), marking it as the third domestic company to obtain such approval [1] Group 1 - The approved product, Trospium Chloride sustained-release capsules, is classified as a Class 4 chemical drug and is considered to have passed the consistency evaluation [1] - The primary indication for Trospium Chloride sustained-release capsules is the treatment of overactive bladder syndrome [1]

Core Insights - The company, Stone Four Pharmaceutical Group, has obtained the production registration approval from the National Medical Products Administration of China for the sustained-release capsules of Trospium Chloride (4mg) [1] - This approval classifies the drug as a Class 4 chemical drug and is considered equivalent to passing the consistency evaluation, making the company the third domestic enterprise to receive such approval [1] - Trospium Chloride sustained-release capsules are primarily used for the treatment of overactive bladder syndrome [1]

Core Viewpoint - The company has received the production registration approval for Trospium Chloride Extended-Release Capsules (4mg) from the National Medical Products Administration of China, marking it as the third domestic company to obtain this approval [1] Group 1: Company Developments - The approval is classified as a Class 4 chemical drug and is considered equivalent to passing the consistency evaluation [1] - Trospium Chloride Extended-Release Capsules are primarily used for the treatment of overactive bladder syndrome [1]

本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 香港，二零二五年十一月二十八日 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團已取得中國國家藥品監督管理局有關酒石酸托特羅定緩釋膠囊(4mg)的藥品生產註冊批 件，屬於化學藥品第4類，視同通過一致性評價，是國內企業第三家獲批。酒石酸托特羅定緩釋 膠囊主要用於治療膀胱過度活動症。 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 周興揚 ...

Core Viewpoint - The company Shijiazhuang Pharmaceutical Group has received approval from the National Medical Products Administration of China for its Vitamin A Palmitate to be registered as an active pharmaceutical ingredient for use in marketed formulations [1] Group 1 - The approved Vitamin A Palmitate is primarily used in fat-soluble vitamin injection solutions to supplement vitamins [1]

Core Viewpoint - The company Shijiazhuang Pharmaceutical Group has received approval from the National Medical Products Administration of China for its Vitamin A Palmitate to be used as an active pharmaceutical ingredient in marketed formulations [1] Group 1 - The approved Vitamin A Palmitate is primarily used in fat-soluble vitamin injection solutions to supplement vitamins [1]